Lumos Pharma (NASDAQ:LUMO) Rating Increased to Strong-Buy at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I upgraded shares of Lumos Pharma (NASDAQ:LUMO) to a strong-buy rating in a report published on Tuesday, Zacks.com reports.

Separately, Oppenheimer lowered their price target on Lumos Pharma from $16.00 to $13.00 and set an outperform rating for the company in a report on Friday, August 2nd.

Lumos Pharma Stock Up 2.6 %

LUMO opened at $3.94 on Tuesday. The stock has a market capitalization of $31.99 million, a price-to-earnings ratio of -0.86 and a beta of 0.78. Lumos Pharma has a twelve month low of $1.37 and a twelve month high of $4.55. The company has a 50-day simple moving average of $3.03 and a 200 day simple moving average of $2.68.

Lumos Pharma (NASDAQ:LUMO) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.33. Lumos Pharma had a negative net margin of 2,405.72% and a negative return on equity of 157.99%. The business had revenue of $0.49 million for the quarter. During the same quarter in the prior year, the business posted ($1.09) EPS. Sell-side analysts anticipate that Lumos Pharma will post -2.56 EPS for the current fiscal year.

Lumos Pharma Company Profile

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.